We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+2.97%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.74B
AUM Growth
+$71.7M
Cap. Flow
+$132M
Cap. Flow %
7.63%
Top 10 Hldgs %
59.59%
Holding
81
New
17
Increased
17
Reduced
15
Closed
14

Top Buys

Rank Stock Value
1
JBIO
Jade Biosciences
JBIO
+$85.8M
2
VERA icon
Vera Therapeutics
VERA
+$45.3M
3
BIIB icon
Biogen
BIIB
+$33.5M
4
HRTX icon
Heron Therapeutics
HRTX
+$23.3M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$22.6M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$42.1M
2
LLY icon
Eli Lilly
LLY
+$33.7M
3
MRUS
Merus
MRUS
+$27.4M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$17.9M
5
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$12.6M

Sector Composition

Rank Sector Weight
1 Healthcare 93.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLDX icon
51
Celldex Therapeutics
CLDX
$2.77B
$4.5M 0.26%
+134,724
New +$3.7M
MIRM icon
52
Mirum Pharmaceuticals
MIRM
$6.89B
$4.49M 0.26%
259,465
-216,936
-46% -$3.89M
JNCE
53
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$4.25M 0.24%
624,756
+112,934
+22% +$938K
FATE icon
54
Fate Therapeutics
FATE
$281M
$4.03M 0.23%
46,386
-8,409
-15% -$678K
ALGS icon
55
Aligos Therapeutics
ALGS
$25.2M
$3.34M 0.19%
6,562
-859
-12% -$548K
CCXI
56
CALL
DELISTED
ChemoCentryx, Inc.
CCXI
$2.88M 0.17%
+215,000
New +$5.3M
OTIC
57
DELISTED
Otonomy, Inc.
OTIC
$2.79M 0.16%
1,251,256
– –
REPL icon
58
Replimune Group
REPL
$814M
$2.75M 0.16%
71,661
-70,548
-50% -$2.41M
BCRX icon
59
BioCryst Pharmaceuticals
BCRX
$2.37B
$2.51M 0.14%
158,609
-220,165
-58% -$2.99M
ACAD icon
60
CALL
Acadia Pharmaceuticals
ACAD
$4.25B
$2.44M 0.14%
+100,000
New +$2.26M
TCRR
61
PUT
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$2.29M 0.13%
+139,700
New +$2.82M
SYBX
62
DELISTED
Synlogic
SYBX
$2.24M 0.13%
38,331
– –
SVRA icon
63
Savara
SVRA
$1.13B
$2.17M 0.13%
1,278,424
-459,026
-26% -$826K
PDSB icon
64
PDS Biotechnology
PDSB
$38.1M
$1.79M 0.1%
142,635
– –
CTIC
65
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$429K 0.02%
+171,619
New +$412K
SRRA
66
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$49K ﹤0.01%
+2,500
New +$45.4K
LONA
67
LeonaBio Inc
LONA
$69.4M
– –
-50,917
Closed -$9.37M
GILD icon
68
CALL
Gilead Sciences
GILD
$161B
– –
-300,000
Closed -$19.4M
HRTX icon
69
CALL
Heron Therapeutics
HRTX
$86.3M
– –
-250,000
Closed -$4.05M
JAZZ icon
70
Jazz Pharmaceuticals
JAZZ
$15.9B
– –
-255,928
Closed -$42.1M
LLY icon
71
Eli Lilly
LLY
$1.07T
– –
-180,501
Closed -$33.7M
MRUS
72
DELISTED
Merus
MRUS
– –
-1,311,039
Closed -$27.4M
PBYI icon
73
Puma Biotechnology
PBYI
$406M
– –
-344,917
Closed -$3.35M
SNDX icon
74
Syndax Pharmaceuticals
SNDX
$1.84B
– –
-298,644
Closed -$6.68M
XLV icon
75
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$42.1B
– –
-400,000
Closed -$46.7M
1 2
3
4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q2 2021 Portfolio in Review

As of Q2 2021, Sofinnova Investments held 81 positions worth $1.74B, up 4.3% from $1.66B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Sofinnova Investments deployed $132M of net new capital in Q2 2021, opening 17 new positions and adding to 17 existing holdings. Its largest new stake was Jade Biosciences: 107,391 shares worth $85.8M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier.

On the sell side, the largest reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $17.9M trimmed.

  • Sofinnova Investments's largest Q2 2021 buy was Jade Biosciences: 107,391 shares worth $85.8M.
  • Sofinnova Investments added most to Insulet in Q2 2021, an estimated $13.9M increase.
  • Sofinnova Investments's biggest Q2 2021 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $17.9M.
  • Sofinnova Investments fully exited Jazz Pharmaceuticals in Q2 2021, selling an estimated $42.1M.
  • Sofinnova Investments's ten largest holdings make up 60% of its $1.74B portfolio in Q2 2021.
  • Sofinnova Investments opened 17 new positions and closed 14 in Q2 2021.
  • Sofinnova Investments's portfolio value rose 4.3% quarter-over-quarter to $1.74B.

Based on Sofinnova Investments's 13F filing for Q2 2021, filed 16 Aug 2021.